Differences in conformational dynamics of [Pt3(HPTAB)]6+ DNA adducts with various cross-linking modes

Nucleic Acids Research

Volumn 37, Issue 17, 2009, Pages 5930-5942

  Zhu, Yanyan ^a   Wang, Yan ^a   Chen, Guangju ^a  

^a BEIJING NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; N,N,N',N',N'',N'' HEXAKIS(2 PYRIDYLMETHYL) 1,3,5 TRIS(AMINOMETHYL)BENZENE; PLATINUM DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DNA ADDUCT; DNA BINDING; DNA CONFORMATION; DNA CROSS LINKING; DNA DAMAGE; HYDROGEN BOND; MOLECULAR DYNAMICS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SIMULATION;

ANTINEOPLASTIC AGENTS; BASE PAIRING; COMPUTER SIMULATION; CROSS-LINKING REAGENTS; DNA ADDUCTS; HYDROGEN BONDING; MODELS, MOLECULAR; NUCLEIC ACID CONFORMATION; ORGANOPLATINUM COMPOUNDS; PRINCIPAL COMPONENT ANALYSIS;

EID: 73049085473     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkp618     Document Type: Article

References (68)

1. Hegmans, A., Berners-Price, S.J., Davies, M.S., Thomas, D.S., Humphreys, A.S. and Farrell, N. (2004) Long range 1,4 and 1,6-interstrand cross-links formed by a trinuclear platinum complex. Minor groove preassociation affects kinetics and mechanism of cross-link formation as well as adduct structure. J. Am. Chem. Soc., 126, 2166-2180.
2. Jung, Y. and Lippard, S.J. (2007) Direct cellular responses to platinum-induced DNA damage. Chem. Rev., 107, 1387-1407.
3. Berners-Price, S.J., Davies, M.S., Cox, J.W., Thomas, D.S. and Farrell, N. (2003) Competitive reactions of interstrand and intrastrand DNA-Pt adducts: a dinuclear-platinum complex preferentially forms a 1,4-interstrand cross-link rather than a 1,2 intrastrand cross-link on binding to a GG 14-mer duplex. Chem. Eur. J., 9, 713-725.
4. Kasparkova, J., Zehnulova, J., Farrell, N. and Brabec, V. (2002) DNA interstrand cross-links of the novel antitumor trinuclear platinum complex BBR3464. conformation, recognition by high mobility group domain proteins, and nucleotide excision repair. J. Biol. Chem., 277, 48076-48086.
5. Wong, E. and Giandomenico, C.M. (1999) Current status of platinum-based antitumor drugs. Chem. Rev., 99, 2451-2466.
6. Fuertes, M.A., Alonso, C. and Perez, J.M. (2003) Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem. Rev., 103, 645-662.
7. Lin, X. and Howell, S.B. (2006) DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance. Mol. Cancer Ther., 5, 1239-1247.
8. Clodfelter, J.E., Gentry, M.B. and Drotschmann, K. (2005) MSH2 missense mutations alter cisplatin cytotoxicity and promote cisplatin-induced genome instability. Nucleic Acids Res., 33, 3323-3330.
9. Jamieson, E.R. and Lippard, S.J. (1999) Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev., 99, 2467-2498.
10. Duan, Y., Wu, C., Chowdhury, S., Lee, M.C., Xiong, G., Zhang, W., Yang, R., Cieplak, P., Luo, R., Lee, T. et al. (2003) A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J. Comput. Chem., 24, 1999-2012.
11. Reed, S.H. (2005) Nucleotide excision repair in chromatin: the shape of things to come. DNA Repair, 4, 909-918.
12. Wei, M., Cohen, S.M., Silverman, A.P. and Lippard, S.J. (2001) Effects of spectator ligands on the specific recognition of intrastrand platinum-DNA cross-links by high mobility group box and ATA-binding proteins. J. Biol. Chem., 276, 38774-38780.
13. Ramachandran, S., Temple, B.R., Chaney, S.G. and Dokholyan, N.V. (2009) Structural basis for the sequence-dependent effects of platinum-DNA adducts. Nucleic Acids Res., 37, 2434-2448.
14. Pil, P.M. and Lippard, S.J. (1992) Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science, 256, 234-237.
15. Ohndorf, U.M., Whitehead, J.P., Raju, N.L. and Lippard, S.J. (1997) Binding of tsHMG, a mouse testis-specific HMG-domain protein, to cisplatin-DNA adducts. Biochemistry, 36, 14807-14815.
16. Trimmer, E.E., Zamble, D.B., Lippard, S.J. and Essigmann, J.M. (1998) Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities. Biochemistry, 37, 352-362.
17. Dunham, S.U. and Lippard, S.J. (1997) DNA sequence context and protein composition modulate HMG-domain protein recognition of ciplatin-modified DNA. Biochemistry, 36, 703-710.
18. Chow, C.S., Whitehead, J.P. and Lippard, S.J. (1994) HMG domain proteins induce sharp bends in cisplatin-modified DNA. Biochemistry, 33, 15124-15130.
19. Lo, Y.C., Ko, T.P., Su, W.C., Su, T.L. and Wang, A.H. (2009) Terpyridine-platinum(II) complexes are effective inhibitors of mammalian topoisomerases and human thioredoxin reductase 1. J. Inorg. Biochem., 103, 1082-1092.
20. Ahmadi, R., Urig, S., Hartmann, M., Helmke, B.M., Koncarevic, S., Allenberger, B., Kienhoefer, C., Neher, M., Steiner, H.H., Unterberg, A. et al. (2006) Antiglioma activity of 2,2':6', 2"-terpyridineplatinum(II) complexes in a rat model-effects on cellular redox metabolism. Free Radic. Biol. Med., 40, 763-778.
21. Witte, A.B., Anestål, K., Jerremalm, E., Ehrsson, H. and Arnér, E.S. (2005) Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic. Biol. Med., 39, 696-703.
22. Becker, K., Herold-Mende, C., Park, J.J., Lowe, G. and Schirmer, R.H. (2001) Human thioredoxin reductase is efficiently inhibited by (2,2':6',2"-terpyridine)platinum(II) complexes. Possible implications for a novel antitumor strategy. J. Med. Chem., 44, 2784-2792.
23. Reedijk, J. (2003) New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA. Proc. Natl Acad. Sci. USA, 100, 3611-3616.
24. Wheate, N.J. and Collins, J.G. (2003) Multi-nuclear platinum complexes as anti-cancer drugs. Coord. Chem. Rev., 241, 133-145.
25. Cox, J.W., Berners-Price, S.J., Davies, M.S., Qu, Y. and Farrell, N. (2001) Kinetic analysis of the stepwise formation of a long-range DNA interstrand cross-link by a dinuclear platinum antitumor complex: evidence for aquated intermediates and formation of both kinetically and thermodynamically controlled conformers. J. Am. Soc. Chem., 123, 1316-1326.
26. Lowe, G., Droz, A.S., Vilaivan, T., Weaver, G.W., Tweedale, L.,c Pratt, J.M., Rock, P., Yardley, V. and Croft, S.L. (1999) Cytotoxicity of (2,2':6',2"-Terpyridine)platinum(II) Complexes to Leishmania donovani, Trypanosoma cruzi, and Trypanosoma brucei. J. Med. Chem., 42, 999-1006.
27. Komeda, S., Lutz, M., Spek, A.L., Yamanaka, Y., Sato, T., Chikuma, M. and Reedijk, J. (2002) A novel isomerization on interaction of antitumor-active azole-bridged dinuclear platinum(II) complexes with 9-ethylguanine. platinum(II) atom migration from N2 to N3 on 1,2,3-triazole. J. Am. Soc. Chem., 124, 4738-4746.
28. Oehlsen, M.E., Qu, Y. and Farrell, N. (2003) Reaction of polynuclear platinum antitumor compounds with reduced glutathione studied by multinuclear (1H, 1H-15N gradient heteronuclear single-quantum coherence, and 195Pt) NMR spectroscopy. Inorg. Chem., 42, 5498-5506.
29. Weissm, R.B. and Christian, M.C. (1993) New cisplatin analogue in development. Drugs, 46, 360-373.
30. Lamers, M.H., Perrakis, A., Enzlin, J.H., Winterwerp, H.H.K., Wind, N.D. and Sixma, T.K. (2000) The crystal structure of DNA mismatch repair protein MutS binding to a G.T mismatch. Nature, 407, 711-717.
31. Obmolova, G., Ban, C., Hsieh, P. and Yang, W. (2000) Crystal structures of mismatch repair protein MutS and its complex with a substrate DNA. Nature, 407, 703-711.
32. Jodrell, D.I., Evans, T.R.J., Steward, W., Cameron, D., Prendiville, J., Aschele, C., Noberasco, C., Lind, M., Carmichael, J., Dobbs, N. et al. (2004) Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma. Eur. J. Cancer, 40, 1872-1877.
33. Jansen, B.A.J., Zwan, J.v.d., Reedijk, J., Dulk, H.d. and Brouwer, J. (1999) A tetranuclear platinum compound designed to overcome cisplatin resistance. Eur. J. Inorg. Chem., 9, 1429-1433.
34. Farrell, N. (2000) In Kelland, L.R. and Farrell, N.P. (eds), Platinum-Based Drugs in Cancer Therapy. Humana Press Inc., Totowa, New Jersey.
35. Brabec, V., Kasparkova, J., Vrana, O., Novakova, O., Cox, J.W., Qu, Y. and Farrell, N. (1999) DNA modifications by a novel bifunctional trinuclear platinum phase I anticancer agent. Biochemistry, 38, 6781-6790.
36. Qu, Y., Farrell, N., Kasparkova, J. and Brabec, V. (1997) DNA binding of properties of trinuclear platinum complex. J. Inorg. Chem., 67, 174.
37. Roberts, J.D., Peroutka, J. and Farrell, N. (1999) Cellular pharmacology of polynuclear platinum anti-cancer agents. J. Inorg. Biochem., 77, 51-57.
38. Zhao, Y., He, W., Shi, P., Zhu, J., Qiu, L., Lin, L. and Guo, Z. (2006) A positively charged trinuclear 3N-chelated monofunctional platinum complex with high DNA affinity and potent cytotoxicity. Dalton Trans., 2617-2619.
39. Zhu, J., Zhao, Y., Zhu, Y., Wu, Z., Lin, M., He, W., Wang, Y., Chen, G., Dong, L., Zhang, J. et al. (2009) DNA cross-linking patterns induced by an antitumor active trinuclear platinum complex and comparison with its dinuclear analogue. Chem. Eur. J., 15, 5245-5253.
40. Chaney, S.G., Campbell, S.L., Bassett, E. and Wu, Y. (2005) Recognition and processing of cisplatin-and oxaliplatin-DNA adducts. Crit. Rev. Oncol. Hematol., 53, 3-11.
41. Sharma, S., Gong, P., Temple, B., Bhattacharyya, D., Dokholyan, N.V. and Chaney, S.G. (2007) Molecular dynamic simulations of cisplatin-and oxaliplatin-d(GG) Intrastand cross-links reveal differences in their conformational dynamics. J. Mol. Biol., 373, 1123-1140.
42. Merajver, S.D., Pham, T.M., Caduff, R.F., Chen, M., Poy, E.L., Cooney, K.A., Weber, B.L. and Frank, T.S. (1995) Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nat. Genet., 9, 439-443.
43. Yang, X.-L. and Wang, A.H.-J. (1999) Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol. Ther., 83, 181-215.
44. Roothan, C.C.J. (1951) New developments in molecular orbital theory. Rev. Mod. Phys., 23, 69-89.
45. Pople, J.A. and Nesbet, R.K. (1954) Self-consistent orbitals for radicals. J. Chem. Phys., 22, 571-572.
46. McWeeny, R. and Diercksen, G. (1968) Self-consistent perturbation theory. II. Extension to open shells. J. Chem. Phys., 49, 4852-4856.
47. Frisch, M.J., Trucks, G.W., Schlegel, H.B., Scuseria, G.E., Robb, M.A., Cheeseman, J.R., J.A. Montgomery, J., Vreven, T., Kudin, K.N., Burant, J.C. et al. (2004) GUASSIAN 03, Revision D.01, Gaussian, Inc., Wallingford, CT.
48. Yao, S., Plastaras, J.P. and Marzilli, L.G. (1994) A molecular mechanics AMBER-type force field for modeling platinum complexes of guanine derivatives. Inorg. Chem., 33, 6061-6077.
49. Chval, Z. and Sip, M. (1998) Force field for platinum binding to adenine and guanine taking into account flexibility of nucleic acids bases. J. Phys. Chem. B, 102, 1659-1661.
50. Cundari, T.R., Fu, W., Moody, E.W., Slavin, L.L., Snyder, L.A., Sommerer, S.O. and Klinckman, T.R. (1996) Molecular mechanics force field for platinum coordination complexes. J. Phys. Chem., 100, 18057-18064.
51. Case, D.A., Darden, T.A., Cheatham, I.T.E., Simmerling, C.L., Wang, J.M., Duke, R.E., Luo, R., Merz, K.M., Pearlman, D.A., Crowley, M. et al. (2006) AMBER9, University of California, San Francisco.
52. Lee, M.C. and Duan, Y. (2004) Distinguish protein decoys by using a scoring function based on a new AMBER force field, short molecular dynamics simulations, and the generalized born solvent model. Proteins Struct. Funct. Bioinform., 55, 620-634.
53. Wang, J.M., Wolf, R.M., Caldwell, J.W., Kollamn, P.A. and Case, D.A. (2004) Development and testing of a general Amber force field. J. Comput. Chem., 25, 1157-1174.
54. Miyamoto, S. and Kollman, P.A. (1992) Settle: an analytical version of the SHAKE and RATTLE algorithm for rigid water models. J. Comput. Chem., 13, 952-962.
55. Lavery, R. and Sklenar, H. (1988) The definition of generalized helicoidal parameters and of axis curvature for irregular nucleic acids. J. Biol. Struct. Dyn., 6, 63-91.
56. Strahs, D. and Schlick, T. (2000) A-tract bending: insights into experimental structures by computational models. J. Mol. Biol., 301, 643-663.
57. Amadei, A., Linssen, A.B., Groot, B.L.D., Aalten, D.M.V. and Berendsen, H.J. (1996) An efficient method for sampling the essential subspace of proteins. J. Biomol. Struct. Dyn., 13, 615-623.
58. Amadei, A., Linssen, A.B.M. and Berendsen, H.J.C. (1993) Essential dynamics of proteins. Proteins: Structure, Function, and Genetics, 17, 412-425.
59. Yamaguchi, H., Aalten, D.M.V., Pinak, M., Furukawa, A. and Osman, R. (1998) Essential dynamics of DNA containing a cis.syn cyclobutane thymine dimer lesion. Nucleic Acids Res., 26, 1939-1946.
60. Teeter, M.M. and Case., D.A. (1990) Harmonic and quasiharmonic descriptions of crambin. J. Phys. Chem., 94, 8091-8097.
61. van Aalten, D.M., Findlay, J.B., Amadei, A. and Berendsen, H.J. (1995) Essential dynamics of the cellular retinol-binding protein evidence for ligand-induced conformational changes. Protein Eng., 8, 1129-1135.
62. Yang, D., Boom, S.S.G.E.v., Reedijk, J., Boom, J.H.V. and Wang, A.H.-J. (1995) Structure and isomerization of an intrastrand cisplatin-cross-linked octamer DNA duplex by NMR analysis. Biochemistry, 34, 12912-12920.
63. Spingler, B., Whittington, D.A. and Lippard, S.J. (2001) 2.4Å crystal structure of an oxaliplatin 1,2-d(GpG) intrastrand cross-link in a DNA dodecamer duplex. Inorg. Chem., 40, 5596-5602.
64. Marzilli, L.G., Saad, J.S., Kuklenyik, Z., Keating, K.A. and Xu, Y. (2001) Relationship of solution and protein-bound structures of DNA duplexes with the major intrastrand cross-link lesions formed on cisplatin binding to DNA. J. Am. Soc. Chem., 123, 2764-2770.
65. Takahara, P.M., Frederick, C.A. and Lippard, S.J. (1996) Crystal structure of the anticancer drug cisplatin bound to duplex DNA. J. Am. Soc. Chem., 118, 12309-12321.
66. Tzou, W.S. and Hwang, M.J. (1999) Modeling helix-turn-helix protein-induced DNA bending with knowledge-based distance restraints. Biophys. J., 77, 1191-1205.
67. Neidle, S. (1994) DNA Structure and Recognition. Oxford University Press, Oxford.
68. Abu-Surrah, A.S. and Kettunen, M. (2006) Platinum group antitumor chemistry: design and development of new anticancer drugs complementary to cisplatin. Curr. Med. Chem., 13, 1337 1357.